Flibanserin Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 100 mg
Reference Brands: Addyi(US)
Category:
Sexual Wellness
Flibanserin is a serotonin receptor modulator that increases sexual desire by balancing neurotransmitters involved in mood and arousal. It reduces hypoactive sexual desire disorder (HSDD) symptoms, improves libido, and enhances intimacy. Benefits include improved sexual motivation, better quality of life, and increased confidence for women experiencing sexual desire issues.
Flibanserin tablet is available in Tablet
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flibanserin tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flibanserin tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flibanserin tablets, marketed as Addyi, are approved in the US by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Regulatory requirements include a comprehensive dossier with clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA conducts detailed review processes, while the EU’s EMA assesses compliance with regional safety and quality standards—though approval in Europe remains pending or varies by country.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing